Recommandé
Contenu connexe
Tendances
Tendances (20)
Similaire à K. thanavaro the indications and uses of the novel anticoagulants
Similaire à K. thanavaro the indications and uses of the novel anticoagulants (20)
Plus de Alysia Smith
Plus de Alysia Smith (10)
Dernier
Dernier (20)
K. thanavaro the indications and uses of the novel anticoagulants
- 1. The Indications and Uses of the Novel Anticoagulants (NOACs): Kristin L. Thanavaro, MD
- 2. Overview: • Warfarin • NOACs: Dabigatran, Rivaroxaban, Apixaban and Edoxaban • Indications, dosing • Interruption for surgery • Management of bleeding, reversal agents • Switching between agents • How to choose the right one for your patient?
- 3. The Clotting Cascade: • Warfarin inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX and X) and Proteins C and S
- 4. Warfarin: • Gold standard for prevention of systemic embolism • Indications: atrial fibrillation (valvular), deep venous thrombosis, pulmonary embolism, ventricular thrombus • Peak effect 72 hours, predominately hepatic metabolism • Inexpensive, well-studied, reversible • But requires frequent blood monitoring, has interactions with food and medication (CYP2C9), and can be influenced by genetic polymorphisms
- 5. NOACs: • Dabigatran —Direct thrombin inhibitor • Rivaroxaban • Apixaban —Factor Xa inhibitors • Edoxaban *All studies compared to dose-adjusted Warfarin INR 2-3 (non-inferiority trials) *No head-to-head trials to date
- 6. The Clotting Cascade: Action of NOACs
- 7. Dabigatran: • First approved NOAC in the US • Dabigatran elexilate (prodrug) hydrolyzed to active metabolite • Direct thrombin inhibitor (free and clot-bound thrombin) – Inhibits multiple procoagulant pathways
- 8. Dabigatran: Pharmacokinetics and Dosing • 80% renal excretion • Plasma peak 2 hours, half-life 12-17 hours • Only 35% protein bound For Non-valvular AF/Systemic Embolism: • 150 mg bid • 75 mg bid if CrCl 15-30 mL/min • Contraindicated if CrCl < 15 mL/min • *110 mg bid dose in RE-LY was not approved
- 9. Dabigatran vs. Warfarin • Similar efficacy in preventing systemic embolism • No more major bleeding • More GI bleeding/dyspepsia • Less hemorrhagic stroke • Slightly higher risk of MI (0.8% vs 0.64%) in post-hoc analysis. More likely protective effect of Warfarin than direct dabigatran effect.
- 10. Dabigatran: Adverse Effects • Mostly GI • Pain/burning in throat, rash • Interactions with P-glycoprotein inhibitors • Dose reduce Dabigatran: ketoconazole, dronedarone • Do not use Dabigatran: Rifampin • Consider alternative anticoagulant if renal impairment: amiodarone, verapamil, diltiazem
- 11. Dabigatran: Interruption for Surgery Creatinine Clearance (mL/min) Low-risk Surgery High-Risk Surgery >50 24 hours 2 days 31-50 2 days 4 days < 30 4 days 6 days Adapted from Fawole, Daw and Crowther. Cleveland Clinic Journal of Medicine (2013) 80:7, 447.
- 12. Switching to/from Dabigatran: Conversion: Dosing: Warfarin to Dabigatran • Stop Warfarin, start Dabigatran when INR<2 Dabigatran to Warfarin • CrCl > 50: Start Warfarin. Stop Dabigatran 3 days later • CrCl 30-50: Start Warfarin. Stop Dabigatran 2 days later • CrCl 15-30: Start Warfarin. Stop Dabigatran 1 day later Parenteral Agent to Dabigatran • LMWH: stop LMWH, start Dabigatran 0-2 hours before next dose LMWH due • Unfractionated heparin: start Dabigatran when stopping IV infusion Dabigatran to Parenteral Agent • CrCl > 30: start parenteral agent 12 hours after last Dabigatran dose • CrCl < 30: start parenteral agent 24 hours after last Dabigatran dose Adapted from Kovacs et al. JACC (2015) 65:13, 1344.
- 13. The Clotting Cascade: Action of NOACs
- 14. Rivaroxaban: • First factor Xa inhibitor approved • Binds reversibly to free and platelet-bound factor Xa • Peak plasma concentration in 2-4 hours • Half life 5-9 hours (9-13 elderly) • 66% renal excreted, hepatic metabolism • 95% protein bound
- 15. Rivaroxaban: Dosing • Systemic Embolism in non-valvular AF: – 20mg with evening meal for CrCl>50 mL/min – 15mg with evening meal for CrCl 15-50 mL/min – Contraindicated if CrCl < 15 mL/min • Drug interactions (potentiate effects): – Ketoconazole, itraconazole – Ritonavir, indinavir – Conivaptan – Amiodarone,verapamil, diltiazem – Rifampin (*decrease action)
- 16. Rivaroxaban vs. Warfarin • Non-inferior to Warfarin in preventing stroke and systemic embolism • Similar rates of major bleeding events • More clinically relevant bleeding events – (2.8% vs. 1.2%) • Less intracranial hemorrhage and fatal bleeding
- 17. Rivaroxaban: Interruption for Surgery Creatinine Clearance (mL/min) Low-risk Surgery High-Risk Surgery >30 24 hours 2 days < 30 2 days 4 days Adapted from Fawole, Daw and Crowther. Cleveland Clinic Journal of Medicine (2013) 80:7, 447.
- 18. Switching to/from Rivaroxaban: Conversion: Dosing: Warfarin to Rivaroxaban • Stop Warfarin, start Rivaroxaban when INR<3 Rivaroxaban to Warfarin • Stop Rivaroxaban and start Warfarin/parenteral agent when next dose of Rivaroxaban would be due. Discontinue parenteral agent when INR is in range Parenteral Agent to Rivaroxaban • LMWH: stop LMWH, start Rivaroxaban 0-2 hours before next dose LMWH due • Unfractionated heparin: start Rivaroxaban when stopping IV infusion Rivaroxaban to Parenteral Agent • Discontinue Rivaroxaban, start parenteral agent at the time the next dose of Rivaroxaban would be due Adapted from Kovacs et al. JACC (2015) 65:13, 1344.
- 19. Apixaban: • Factor Xa inhibitor • Peak plasma concentration in 3-4 hours • Half life 10-14 hours • 27% renal excreted, 63% fecal excreted, hepatic metabolism • 87% protein bound
- 20. Apixaban: Dosing • Systemic Embolism/ NVAF: • 5 mg bid • 2.5 mg bid if two out of three factors met: • Age > 80 years • Body weight <60 kg • Creatinine >1.5 mg/dL • ESRD on HD: – 5mg bid – Decrease to 2.5mg bid if > 80 yo or < 60 kg
- 21. Apixaban: Drug Interactions • Dose reduce with: – Ketoconazole/itraconazole – Ritonavir – Clarithromycin • If already on 2.5mg dose, Apixaban should be avoided • *Rifampin—decreases Apixaban action
- 22. Apixaban vs. Warfarin • Superior to Warfarin in preventing stroke and systemic embolism (1.27% vs. 1.6%) • Less major bleeding events (2.1% vs. 3.1%) – ICH • Slightly less all cause mortality (secondary outcome)
- 23. Apixaban: Interruption for Surgery Creatinine Clearance (mL/min) Low-risk Surgery High-Risk Surgery >30 24 hours 2 days < 30 2 days 4 days Adapted from Fawole, Daw and Crowther. Cleveland Clinic Journal of Medicine (2013) 80:7, 447.
- 24. Switching to/from Apixaban: Conversion: Dosing: Warfarin to Apixaban • Stop Warfarin, start Apixaban when INR<2 Apixaban to Warfarin • Stop Apixaban and start Warfarin/parenteral agent when next dose of Apixaban would be due. Discontinue parenteral agent when INR is in range Parenteral Agent to Apixaban • LMWH: stop LMWH, start Apixaban when next dose LMWH due • Unfractionated heparin: start Apixaban when stopping IV infusion Apixaban to Parenteral Agent • Discontinue Apixaban, start parenteral agent at the time the next dose of Apixaban would be due Adapted from Kovacs et al. JACC (2015) 65:13, 1344.
- 25. Edoxaban: • Newest factor Xa inhibitor • Rapid onset of action (peak effect 1-2 hours) • 35% renal excretion, hepatic metabolism • Cannot be used with CrCl > 95 mL/min because the drug may clear too quickly (increased risk of ischemic CVA) – CrCl 50-94 mL/min: 60mg daily – CrCl 15-50 mL/min: 30mg daily • May need dose reduction: verapamil, quinidine, dronedarone • Avoid with rifampin (decrease action)
- 26. Edoxaban vs. Warfarin • Similar to Warfarin in preventing stroke and systemic embolism • Less major bleeding, hemorrhagic stroke • More gastrointestinal bleeding
- 27. Edoxaban: Interruption for Surgery • Hold for 24 hours for low-risk bleeding procedure • Hold for 48 hours for high-risk bleeding procedure
- 28. Switching to/from Edoxaban: Conversion: Dosing: Warfarin to Edoxaban • Stop Warfarin, start Edoxaban when INR < 2.5 Edoxaban to Warfarin • Stop Edoxaban and start Warfarin/parenteral agent when next dose of Edoxaban would be due. Discontinue parenteral agent when INR is in range -OR- • Dose reduced Exoxaban by 50% and start Warfarin. Check INR weekly and stop Edoxaban when INR > 2 Parenteral Agent to Edoxaban • LMWH: stop LMWH, start Edoxaban when next dose LMWH due • Unfractionated heparin: start Edoxaban 4 hours after stopping IV infusion Edoxaban to Parenteral Agent • Discontinue Edoxaban, start parenteral agent at the time the next dose of Edoxaban would be due Adapted from Kovacs et al. JACC (2015) 65:13, 1344.
- 30. Factor Xa Inhibitors: • No antidote, but short half lives • Vitamin K and FFP do not reverse the anticoagulant effects. Not dialyzable • Life Threatening Bleeding: • Gastric lavage/activated charcoal (2-3 hrs) • Give blood/platelets • 4 Factor Plasma Prothrombin Concentrate (PCC)—II, VII, IX, X. – May have some clinical benefit, but data are lacking – Risk of MI and systemic thrombosis – Expensive • Reversal agent pending (Andexanet alfa, Aripazine)
- 31. Bleeding with Dabigatran: • Dialysis • Idarucizumab: antibody to Dabigatran • 5 grams IV X 1 (may consider repeat dose) • Completely reverses the anticoagulant effects of Dabigatran within minutes, restores hemostasis • No evidence of prothrombotic effects
- 32. DVT/PE Treatment: Indication Dabigatran Rivaroxaban Apixaban Edoxaban Prevention of VTE Not indicated 10 mg daily 2.5 mg bid Not indicated Treatment of VTE 150 mg bid after parenteral tx (if CrCl> 30 mL/min) 15 mg bid for 21 days then 20mg daily 10mg bid then 5 mg bid 60 mg daily after parenteral treatment if CrCl 15-50 mL/min Preventing Recurrent VTE 150mg bid if CrCl > 30 mL/min 20mg daily 2.5 mg bid Not indicated Adapted from Roca and Roca. Cleveland Clinic Journal of Medicine (2015) 82:12,849.
- 33. Choosing the Right Anticoagulant: • Warfarin: – Moderate+ valve disease/prosthetic valves – LV thrombus • Other considerations: – Reversibility – Once daily vs. bid dosing (compliance) – Renal function – Co-administration of other medications – Cost – Patient preference
- 34. Summary: • NOACs: indications, dosing, dose adjustment • Interruption for surgery • Switching between anticoagulants • Management of bleeding and reversal agents • Choosing the right one for your patient
- 35. Thank you!
- 36. Works Cited: • Fawole A, Daw HA and Crowther MA. Cleveland Clinic Journal of Medicine (2013) 80:7. • Gonsalves WI, Pruthi RK and Patnaik MM. Mayo Clinic Proceedings (2013) 88:5. • Kovacs RJ and Flaker GC et al. JACC (2015) 65:13. • Pollack CV and Reilly PA et al. NEJM (2015) 373:6. • Roca B and Roca M. Cleveland Clinic Journal of Medicine (2015) 82:12. • Tanaka-Esposito C and Chung MK. Cleveland Clinic Journal of Medicine (2015) 82:1.
Notes de l'éditeur
- We’ll see later that the NOACs act further down in the common pathway
- By inhibiting thrombin, dabigatran inhibits multiple procoagulant pathways
- There was less bleeding than warfarin with 110mg dose (RE-LY) Less ischemic stroke
- All these medications potentiate the action of Dabigatran
- Mostly bound to albumin, cannot be dialyzed out
- CYP3A4 and P-glycoprotein inhibitors increase Rivaroxaban exposure
- ROCKET-AF Trial
- Less renal excretion than Rivaroxaban, more kidney friendly Ok for use in mild hepatic impairment, but avoid if modest-advanced liver failure
- 2 large Apixaban trials were AVERROES (Apixaban vs. ASA) and ARISTOTLE (Apxiaban vs. Warfarin) Of note, pts with Cr >2.5 or CrCL < 25 mL/min were excluded from the AF (and acute VTE) studies. But, approved later for use in ESRD.
- ARISTOTLE
- Half life 10 hours, 50% protein bound, No CYPP450 metabolism, but uses P-gp transporter
- ENGAGE-TIMI AF Trial
- REVERSE-AD study
- Rivaroxaban/Apixaban have broad range of uses. Edoxaban and Dabigatran cannot be used for prevention of VTE and are only used for treatment after parenteral treatment.